坦桑尼亚PCV13时代5岁以下儿童鼻咽部非疫苗肺炎链球菌血清型定植的出现
该研究在坦桑尼亚PCV13推广前后开展两项横断面调查,共纳入539名5岁以下儿童,比较鼻咽拭子分离的肺炎链球菌血清型分布。PCV13前疫苗型占55%(61株),PCV13后降至23.3%(89株);PCV13后最常见为15B/C(10.5%)和3型(7.6%),并出现14种PCV13前未检测到的非疫苗血清型。
要点
- PCV13推广后疫苗型肺炎链球菌定植比例从55%降至23.3%。
- PCV13后常见血清型为15B/C(10.5%)和3型(7.6%)。
- PCV13后出现14种PCV13前未检测到的非疫苗血清型。
核心结论
- PCV13推广后儿童鼻咽部疫苗型肺炎链球菌定植减少,非疫苗血清型定植出现并需持续监测。
研究设计与样本
- 两项横断面研究,共纳入539名5岁以下儿童,分别于PCV13推广前和推广后采集鼻咽拭子。
- PCV13推广后的研究仅纳入完成PCV13接种程序的儿童。
主要发现
- PCV13推广前疫苗型血清型占55%(61株),推广后占23.3%(89株)。
- PCV13推广前最常见血清型为19F(20.7%,n=23)和6B(9.9%,n=11)。
- PCV13推广后最常见血清型为15B/C(10.5%,n=40)和3型(7.6%,n=29)。
- PCV13推广后出现14种PCV13推广前未检测到的非疫苗血清型。
临床怎么用
- 在PCV13高接种率地区应持续监测肺炎链球菌血清型定植变化。
- 关注非疫苗血清型定植对侵袭性肺炎链球菌病保护的潜在影响。
局限性
- 原文提及需进一步监测以评估定植变化及其对侵袭性肺炎链球菌病保护的意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To determine the impact of pneumococcal vaccination on nasopharyngeal carriage in Tanzania, we assessed the serotype distribution of S. pneumoniae isolated from nasopharyngeal swab samples. These samples were collected in 539 children below the age of 5 years in two cross-sectional studies, one before and one after PCV13 rollout. In the second study, post-PCV13 rollout, only children who completed the PCV13 vaccination schedule, were included. From the study conducted before the introduction of PCV13, 61 (55 %) of S. pneumoniae serotypes were vaccine types, compared to 89 (23.3 %) post-PCV13. The most common serotypes in the pre-PCV13 period were 19F (n = 23, 20.7 %) and 6B (n = 11, 9.9 %). In the post-PCV13 era, serotypes 15B/C (n = 40, 10.5 %), and 3 (n = 29, 7.6 %) were most prevalent. We observed the emergence of 14 non-vaccine serotypes not detected in the pre-vaccine era. Further surveillance is needed to assess shifts in carriage and their implications for the protection against invasive pneumococcal disease.
引用
- Ngocho JS, van der Gaast-de Jongh CE, Sebba J, et al. Emergence of non-vaccine Streptococcus pneumoniae serotypes colonizing the nasopharynx of children under five years of age in the 13-valent pneumococcal conjugate vaccine era in Tanzania. A short communication. Vaccine. 2025. PMID: 41481015. doi:10.1016/j.vaccine.2025.127336
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。